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Dear Editor,
A 65-year-old male patient was
transferred to our institution for res-
cue therapy after developing severe
ARDS (PaO2/FiO2 = 51) refractory
to conventional ventilation (FiO2 1,
0, PEEP 12 cm H2O) following
femoral thrombendarterectomy.
Veno-venous ECMO therapy was
initiated on the day of arrival. The
patient was ventilated using a lung-
protective strategy. Treatment with
methylprednisolone (2 mg/kg/day)
had been initiated by the referring
institution and was continued
throughout the patient’s stay in our
ICU. The patient was repeatedly
placed in the prone position. Initial
blood cultures and tracheal secretions
showed Enterococcus and coagulase-
negative Staphylococcus, suggesting
perioperative pneumonia as the
underlying trigger of ARDS. Antibi-
otic treatment consisted of
piperacillin/tazobactam 4.5 g every
8 h. Throughout the first 7 days of
treatment the patient required no
vasopressor support. There were no
signs of further organ failure. Repe-
ated neurological assessment was
unremarkable. Oxygenation and lung
compliance gradually improved
following treatment initiation. A
repeat CT scan of the chest on treat-
ment day 9 showed improved aeration
of lung tissue and a marked resolution
of infiltrates. On treatment day 9 the
patient developed severe sepsis with
multiple organ failure and a rapid
increase of serum creatine kinase.
Clinically there were no signs sug-
gestive of compartment syndrome or
limb ischemia, as monitored contin-
uously by near-infrared spectroscopy.
Duplex ultrasonography showed ade-
quate renal perfusion, and cardiac
assessment by TOE showed no val-
vular pathology suggestive of
endocarditis and a normal left-ven-
tricular function. On treatment day
10, red maculae developed on the
lower extremities and were present
over the whole body surface within
hours, progressing to dermal necrosis
with black eschar formation (Fig. 1).
The patient developed intractable
metabolic acidosis and vasoplegia,
and died on treatment day 11.
Biopsies from skin lesions revealed
cutaneous mucormycosis on culture.
The diagnosis of Absidia corymbifera
was confirmed posthumously by
agent-specific PCR. Repeated blood
cultures and broad-spectrum molecu-
lar analysis of the blood specimen
remained negative. Mycologic exam-
ination of bronchoalveolar lavage
fluid showed no pathogens. Autopsy
was not performed.
ARDS represents a major health
problem, with current estimates
pointing to its incidence being greater
than previously reported [1]. Recent
data suggest a mortality benefit in
severe refractory ARDS by adminis-
tration of corticosteroids [2]. Steroid-
induced immunosuppression is a
potential side effect of this therapy
that has been addressed in the litera-
ture, although none of the randomized
controlled trials on glucocorticoid use
in ARDS have reported an increased
rate of infection [3]. Absidia cor-
ymbifera is a fungal agent belonging
Fig. 1 Skin lesions on the patient’s left leg at different stages of development. a Skin
lesion minutes after initial appearance. b Transformation of the lesion’s core with central
dermal necrosis. c Skin lesion approximately 6 h after appearance showing central, black
eschar formation and subepidermal fluid collection
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to the Mucorales order of Mucormy-
cotina, causing mucormycosis in high
risk subgroups, especially immuno-
compromised patients. Disseminated
cutaneous infection, as presented in
this case, has a dismal prognosis if
surgical debridement and antifungal
therapy are not initiated immediately
or are not applicable [4]. As to our
knowledge, this is the first case of
disseminated mucormycosis descri-
bed in the literature developing under
the special circumstances of high-
dose corticosteroid therapy for severe
ARDS. The potential benefits of cor-
ticosteroid therapy and the relative
safety of its use as described in recent
randomized trials and meta-analyses
should not deter clinicians from per-
forming meticulous infection
surveillance when initiating such
treatment.
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